National Health (Additional Community Supply Support Payment) Determination 2024 (Cth)

PB 94 of 2024

National Health (Additional Community Supply Support Payment) Determination 2024 The Pharmaceutical Benefits Remuneration Tribunal, makes the following determination.

Dated 8 October 2024

Judith Wright Chairperson for and on behalf of the Pharmaceutical Benefits Remuneration Tribunal

Contents 1 Name 2 Commencement 3 Authority 4 Definitions 5 ACSS eligible supplies 6 Amount of ACSS payment

1 Name (1) This instrument is the National Health (Additional Community Supply Support Payment) Determination 2024. (2) This instrument may also be cited as PB 94 of 2024.

2 Commencement (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information Column 1 Column 2 Column 3 Provisions Commencement Date/Details 1. The whole of this instrument The day after this instrument is registered.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument. (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority This instrument is made under paragraph 98B(1)(b) of the National Health Act 1953.

4 Definitions (1) In this instrument: Act means the National Health Act 1953. increased maximum quantity of a pharmaceutical benefit means the maximum quantity or number of units of the benefit or the pharmaceutical item in the benefit that may, in one prescription, be directed to be supplied on any one occasion, for a relevant purpose, under a determination of the Minister under paragraph 85A(2)(a) of the Act. increased maximum quantity prescription means a prescription directing, for a relevant purpose, the supply on any one occasion of the increased maximum quantity of a pharmaceutical benefit. relevant purpose, for a pharmaceutical benefit, means a purpose, mentioned in Schedule 4 to the National Health (Listing of Pharmaceutical Benefits) Instrument 2024 for a purposes code (within the meaning of that instrument) specified in Schedule 1 to that instrument for the benefit, that includes the phrase "The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient". (2) An expression that is used in this instrument and in Part VII of the Act has the same meaning in this instrument as it has in that Part. Note: Examples of such expressions include the following: (a) ACSS eligible supply; (b) ACSS payment; (c) approved pharmacist; (d) pharmaceutical benefit; (e) pharmaceutical item; (f) Schedule equivalent.